NASDAQ:KTWO - K2M Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$27.50
+0.30 (1.20%)
Get New K2M Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KTWO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KTWO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for K2M Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $27.50.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in K2M Group. This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/24/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
i
9/4/2018CowenDowngradeOutperform ➝ Market Perform$28.00 ➝ $27.50Low
i
9/4/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$28.00 ➝ $27.50Low
i
Rating by C. Bijou at Cantor Fitzgerald
8/31/2018OppenheimerDowngradeOutperform ➝ HoldLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/30/2018Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
8/30/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
8/30/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$28.00High
i
Rating by C. Bijou at Cantor Fitzgerald
8/2/2018OppenheimerSet Price TargetBuy$25.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/2/2018Needham & Company LLCBoost Price TargetBuy$23.00 ➝ $29.00High
i
5/31/2018Cantor FitzgeraldInitiated CoverageOverweight$28.00Medium
i
Rating by C. Bijou at Cantor Fitzgerald
5/2/2018Needham & Company LLCReiterated RatingBuy$23.00High
i
5/2/2018OppenheimerSet Price TargetBuy$24.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/1/2018OppenheimerSet Price TargetBuy$24.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/9/2018BarclaysReiterated RatingBuy$25.00Low
i
1/9/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$20.00 ➝ $23.00High
i
12/8/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$26.00 ➝ $20.00Low
i
12/4/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$23.00High
i
11/10/2017OppenheimerReiterated RatingBuy$24.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/3/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00N/A
i
11/2/2017Needham & Company LLCLower Price TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $26.00N/A
i
10/20/2017Needham & Company LLCReiterated RatingBuy$27.00N/A
i
10/18/2017OppenheimerSet Price TargetBuy$24.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/10/2017JMP SecuritiesReiterated RatingOutperform$30.00 ➝ $25.00N/A
i
10/10/2017CowenReiterated RatingOutperform$28.00 ➝ $22.00N/A
i
Rating by Josh Jennings at Cowen Inc
10/10/2017William BlairReiterated RatingOutperformN/A
i
10/10/2017Piper Jaffray CompaniesReiterated RatingOverweight$28.00N/A
i
10/10/2017Wells Fargo & CompanyLower Price TargetOutperform$28.00 ➝ $23.00N/A
i
10/10/2017UBS GroupReiterated RatingBuy$26.00 ➝ $24.00N/A
i
10/9/2017Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$29.00 ➝ $27.00N/A
i
9/28/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00High
i
9/22/2017Royal Bank of CanadaReiterated RatingBuy$26.00Low
i
8/17/2017CowenSet Price TargetBuy$26.00 ➝ $28.00Low
i
Rating by Josh Jennings at Cowen Inc
8/2/2017Needham & Company LLCReiterated RatingBuyHigh
i
8/2/2017OppenheimerSet Price TargetBuy$29.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/20/2017Royal Bank of CanadaReiterated RatingBuy$26.00Low
i
7/19/2017CowenReiterated RatingBuy$26.00Low
i
7/11/2017OppenheimerReiterated RatingBuyMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/28/2017JMP SecuritiesReiterated RatingOutperform$27.00 ➝ $30.00Low
i
6/22/2017OppenheimerReiterated RatingBuyHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/3/2017OppenheimerSet Price TargetBuy$26.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/3/2017Royal Bank of CanadaReiterated RatingBuyLow
i
4/24/2017BarclaysBoost Price TargetOverweight$26.00 ➝ $27.00High
i
4/12/2017JMP SecuritiesReiterated RatingOutperform$27.00Medium
i
4/9/2017CowenReiterated RatingOutperform$21.00 ➝ $26.00Low
i
3/7/2017Needham & Company LLCReiterated RatingBuy$29.00N/A
i
1/11/2017OppenheimerReiterated RatingOutperform$23.00 ➝ $26.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/11/2017BarclaysReiterated RatingBuy$26.00N/A
i
1/10/2017Needham & Company LLCBoost Price TargetStrong-Buy$25.00 ➝ $29.00N/A
i
12/20/2016OppenheimerReiterated RatingOutperformN/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/12/2016Needham & Company LLCBoost Price TargetStrong-Buy$22.00 ➝ $25.00N/A
i
Rating by Michael Matson at Needham & Company LLC
10/10/2016Royal Bank of CanadaInitiated CoverageOutperform$23.00N/A
i
9/16/2016GabelliInitiated CoverageBuy$22.00N/A
i
Rating by J. Tsai at Gabelli
9/13/2016OppenheimerReiterated RatingOutperform$23.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
8/5/2016OppenheimerReiterated RatingOutperform$23.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/5/2016Needham & Company LLCReiterated RatingStrong-Buy$21.00 ➝ $22.00N/A
i
Rating by Michael Matson at Needham & Company LLC
8/4/2016BarclaysBoost Price TargetOverweight$20.00 ➝ $22.00N/A
i
7/19/2016OppenheimerReiterated RatingOutperformN/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/18/2016OppenheimerInitiated CoverageBuy$23.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/22/2016Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Michael Matson at Needham & Company LLC
6/5/2016JMP SecuritiesReiterated RatingBuy$22.00N/A
i
5/23/2016Needham & Company LLCUpgradeBuy ➝ Strong-Buy$21.00N/A
i
Rating by Michael Matson at Needham & Company LLC
5/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00N/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
5/3/2016Piper Jaffray CompaniesReiterated RatingBuy$29.00 ➝ $22.00N/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
5/3/2016Needham & Company LLCReiterated RatingBuy$21.00N/A
i
Rating by Sharon Stein at Needham & Company LLC
5/3/2016Northland SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
4/25/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
(Data available from 4/21/2016 forward)
K2M Group logo
K2M Group Holdings, Inc., a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor. Its complex spine products include EVEREST, MESA, and MESA 2 deformity spinal systems; NILE alternative and proximal fixation spinal systems; MESA rail deformity spinal systems; Cricket spinal correction rod reduction instrumentation; CAPRI corpectomy cage systems; MESA small stature, rail small stature, and mini spinal systems; SERENGETI complex spine minimally invasive retractor systems; RAVINE complex spine lateral access systems; SANTORINI corpectomy cage systems; YUKON OCT spinal systems; and PALO ALTO cervical static corpectomy cage systems. The company's minimally invasive surgery products consist of EVEREST minimally invasive spinal and XT spinal, SERENGETI minimally invasive retractor, MOJAVE PL 3D expandable interbody, RAVINE lateral access, CASCADIA lateral 3D interbody, ALEUTIAN lateral interbody, and TERRA NOVA minimally invasive access systems. In addition, its degenerative spine products comprise EVEREST degenerative spinal, CASCADIA and ALEUTIAN interbody, SAHARA AL expandable stabilization, RHINE cervical disc, CHESAPEAKE interbody, PYRENEES cervical plate, and BLUE RIDGE hybrid cervical plate systems. Further, the company provides Balance ACS, a platform that includes tools to assist surgeons with obtaining authorization from healthcare insurers. K2M Group Holdings, Inc. markets and sells its products through direct sales employees, independent sales agencies, and distributor partners. The company was founded in 2004 and is headquartered in Leesburg, Virginia.
Read More

Today's Range

Now: $27.50
$27.50
$27.50

50 Day Range

MA: N/A

52 Week Range

Now: $27.50
$16.44
$27.50

Volume

N/A

Average Volume

1,848,676 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of K2M Group?

The following Wall Street research analysts have issued reports on K2M Group in the last year:
View the latest analyst ratings for KTWO.

What is the current price target for K2M Group?

0 Wall Street analysts have set twelve-month price targets for K2M Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for K2M Group in the next year.
View the latest price targets for KTWO.

What is the current consensus analyst rating for K2M Group?

K2M Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KTWO.

What other companies compete with K2M Group?

How do I contact K2M Group's investor relations team?

K2M Group's physical mailing address is 600 HOPE PARKWAY SE, LEESBURG VA, 20175. The medical device company's listed phone number is 703-777-3155 and its investor relations email address is [email protected] The official website for K2M Group is www.k2m.com.